Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Adocia    ADOC   FR0011184241

ADOCIA (ADOC)

Delayed Quote. Delayed  - 05/27 05:35:04 pm
54.38 EUR   +0.65%
05/13 ADOCIA : to hold its annual shareholders’ meeting on June 21, ..
04/14 ADOCIA : announces first quarter 2016 results
04/14 ADOCIA : announces first quarter 2016 results
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Adocia
Operates as a clinical-stage biotechnology company

Adocia SA operates as a clinical-stage biotechnology company, which engages in the development of medicines from already approved therapeutic agents.

Its product pipeline includes BioChaperone PDGF, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase I/II clinical trials, as well as in pre-clinical staged for the treatment of diabetes; and Driveln, which is in preclinical stage for the treatment of oncology, The company was founded by Gérard Soula, OLivier Soula, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.



Number of employees : 109 persons.
Sales per Businesses
20142015Delta
EUR (in Million)%EUR (in Million)%
Regenerating Medicine0.704100%36.94100% +5146.59%
Sales per Regions
20142015Delta
EUR (in Million)%EUR (in Million)%
France0.704100%36.94100% +5146.59%
Managers
NameAgeSinceTitle
Gérard Soula PhD, MBA682005Chairman, President & Chief Executive Officer
Valérie Danaguezian-2006Chief Financial Officer & Administrative Director
Olivier Soula PhD, MBA472005Director, Deputy General Manager, Director-R&D
Olivier Martinez PhD, MBA46-Director
Laurent Arthaud54-Director
Dominique Takizawa582011Independent Director
Ekaterina Smirnyagina, PhD492013Independent Director
Rémi Soula PhD, MBA-2005Director-Business Development
David Duracher, PhD--Director-Pharmaceutical Development
Géraldine Favre-Soula--Director-Human Resources Development Department
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 6,846,363 5,235,414 76.5% 4,185 0.1% 76.5%
Shareholders
NameEquities%
Gérard Soula PhD, MBA 898,463 13.1%
BPIFrance Investissement SAS 738,639 10.8%
La Société Hospitalière d'Assurances Mutuelles SA 320,000 4.67%
Olivier Soula PhD, MBA 307,490 4.49%
Rémi Soula PhD, MBA 302,490 4.42%
Alken Asset Management Ltd. 112,158 1.64%
Aviva Investors France SA 78,416 1.15%
Candriam Belgium SA 69,400 1.01%
ACG Management SAS 67,439 0.99%
CDC Entreprises Valeurs Moyennes SAS 65,732 0.96%
Holdings
NameEquities%Valuation
Adocia (ADOC) 4,1850.061%297,376 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
AMGEN, INC.
GILEAD SCIENCES, ..
CELGENE CORPORATI..
REGENERON PHARMAC..
VERTEX PHARMACEUT..
ACTELION LTD
GENMAB A/S
MEDIVATION INC
HUALAN BIOLOGICAL..
JUNO THERAPEUTICS..
TONGHUA DONGBAO P..
NEUROCRINE BIOSCI..
INTERCEPT PHARMAC..
PEPTIDREAM INC
CHINA BIOLOGIC PR..
BEIJING SL PHARMA..
ULTRAGENYX PHARMA..
KITE PHARMA INC
ZHONGYUAN UNION C..
BIOCON LTD
Sector Biotechnology & Medical Research
Adocia : Connections
Institut Mérieux SA
BPIFrance Investissement SAS
FAB Pharma SAS
Alizé Pharma SAS
Lyon Pôle Bourse
iSTAR Medical SA
Lyon Place Financière & Tertiaire
Capricorn Venture Partners NV
Company contact information
115 avenue Lacassagne
FR-69003 Lyon
France

Phone : +33 (0)4 72 610 610
Fax : +33 (0)4 72 36 39 67
Internet : http://www.adocia.com
Markets and indexes
- PEA / SRD eligible : YES / YES
- Euronext Paris
- Compartiment B
- CAC All Shares / CAC All-Tradable, CAC Mid Small, CAC PME, CAC Small, EnterNext© PEA-PME 150, Next 150, Next Biotech, PEA-PME, Tech 40
Stock Exchange Codes
- ISIN Code :  FR0011184241
- Bloomberg Code :  ADOC:FP
- Reuters Code :  ADOC.PA
- Datastream Code :  
© 2016 People , Fundamentals and Ownership    © 2016 Cofisem